An investigation into the role of MIR22HG, a long non-coding RNA encoding miR-22, in CRC progression and response to immunotherapy revealed that MIR22HG is downregulated in CRC tissues, with its loss associated with poor patient prognosis [104]. Here, MIR22HG is linked to colorectal carcinoma.